{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:30:21Z","timestamp":1790767821185,"version":"4.1.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jaut.2019.102399","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T07:41:17Z","timestamp":1577778077000},"page":"102399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Prevention and cure: The major unmet needs in the management of rheumatoid arthritis"],"prefix":"10.1016","volume":"110","author":[{"given":"Kulveer","family":"Mankia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Di Matteo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Emery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaut.2019.102399_bib1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jaut.2019.102399_bib2","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","article-title":"Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis","volume":"48","author":"Rantap\u00e4\u00e4-Dahlqvist","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035296","article-title":"Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis","volume":"7","author":"Sokolove","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jaut.2019.102399_bib4","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1136\/ard.2009.124537","article-title":"Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis","volume":"69","author":"van der Woude","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.jaut.2019.102399_bib5","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3899\/jrheum.140767","article-title":"Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis","volume":"42","author":"Gan","year":"2015","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.jaut.2019.102399_bib6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2013-204154","article-title":"Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis","volume":"73","author":"Shi","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2019.102399_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13075-016-1001-6","article-title":"Antibodies to carbamylated alpha-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies","volume":"18","author":"Reed","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.jaut.2019.102399_bib8","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/art.40562","article-title":"Triple positivity for anti-citrullinated protein autoantibodies, rheumatoid factor, and anti-carbamylated protein antibodies conferring high specificity for rheumatoid arthritis: implications for very early identification of at-risk individuals","volume":"70","author":"Verheul","year":"2018","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"12","key":"10.1016\/j.jaut.2019.102399_bib9","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1136\/annrheumdis-2015-208235","article-title":"Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis","volume":"75","author":"Nam","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.jaut.2019.102399_bib10","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/annrheumdis-2015-208138","article-title":"Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis","volume":"75","author":"van Steenbergen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2019.102399_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.semarthrit.2016.05.002","article-title":"High prevalence of tenosynovial inflammation before onset of rheumatoid arthritis and its link to progression to RA-A combined MRI\/CT study","volume":"46","author":"Kleyer","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102399_bib12","series-title":"MRI Inflammation of the Hand Interosseous Tendons Occurs in Anti-CCP-positive At-Risk Individuals and May Precede the Development of Clinical Synovitis. Annals of the Rheumatic Diseases","author":"Mankia","year":"2019"},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib13","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/ard.2010.139527","article-title":"Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase","volume":"70","author":"van de Sande","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2019.102399_bib14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.21575","article-title":"A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination","volume":"54","author":"Klareskog","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"109","key":"10.1016\/j.jaut.2019.102399_bib15","first-page":"129","article-title":"Is localized autoimmunity the trigger for rheumatoid arthritis? Unravelling new targets for prevention","volume":"20","author":"Mankia","year":"2015","journal-title":"Discov. Med."},{"issue":"6","key":"10.1016\/j.jaut.2019.102399_bib16","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/art.37911","article-title":"Anti-citrullinated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients","volume":"65","author":"Barra","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jaut.2019.102399_bib17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1136\/annrheumdis-2011-200668","article-title":"Antibodies against cyclic citrullinated peptides of IgG, IgA and IgM isotype and rheumatoid factor of IgM and IgA isotype are increased in unaffected members of multicase rheumatoid arthritis families from northern Sweden","volume":"71","author":"Arlestig","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102399_bib18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fimmu.2016.00080","article-title":"Hand to mouth: a systematic review and meta-analysis of the association between rheumatoid arthritis and periodontitis","volume":"7","author":"Fuggle","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2019.102399_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2017.08.001","article-title":"Periodontal disease and periodontal bacteria as triggers for rheumatoid arthritis","author":"Cheng","year":"2017","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"10","key":"10.1016\/j.jaut.2019.102399_bib20","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/art.34539","article-title":"Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis","volume":"64","author":"Scher","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102399_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-213697","article-title":"Porphyromonas gingivalis experimentally induces periodontis and an anti-CCP2-associated arthritis in the rat","author":"Courbon","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"369","key":"10.1016\/j.jaut.2019.102399_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1921","article-title":"Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis","volume":"8","author":"Konig","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.jaut.2019.102399_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.5394","article-title":"Prevalence of periodontal disease and periodontopathic bacteria in anti-cyclic citrullinated protein antibody-positive at-risk adults without arthritis","volume":"2","author":"Mankia","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.jaut.2019.102399_bib24","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1902\/jop.2015.150455","article-title":"Periodontal disease in individuals with a genetic risk of developing arthritis and early rheumatoid arthritis: a cross-sectional study","volume":"87","author":"Bello-Gualtero","year":"2016","journal-title":"J. Periodontol."},{"issue":"7","key":"10.1016\/j.jaut.2019.102399_bib25","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jcpe.13117","article-title":"Periodontal status correlates with anti-citrullinated protein antibodies in first-degree relatives of individuals with rheumatoid arthritis","volume":"46","author":"Loutan","year":"2019","journal-title":"J. Clin. Periodontol."},{"issue":"8","key":"10.1016\/j.jaut.2019.102399_bib26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm.3914","article-title":"The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.jaut.2019.102399_bib27","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/art.40485","article-title":"Dysbiotic subgingival microbial communities in periodontally healthy patients with rheumatoid arthritis","volume":"70","author":"Lopez-Oliva","year":"2018","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"4","key":"10.1016\/j.jaut.2019.102399_bib28","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/odi.12017","article-title":"Effects of periodontal therapy on disease activity and systemic inflammation in rheumatoid arthritis patients","volume":"19","author":"Erciyas","year":"2013","journal-title":"Oral Dis."},{"issue":"2","key":"10.1016\/j.jaut.2019.102399_bib29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.semarthrit.2014.04.009","article-title":"Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis","volume":"44","author":"Kaur","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102399_bib30","article-title":"I would never take preventive medication! Perspectives and information needs of people who underwent predictive tests for rheumatoid arthritis","author":"Mosor","year":"2019","journal-title":"Arthritis Care Res."},{"issue":"10","key":"10.1016\/j.jaut.2019.102399_bib31","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/ard.2007.075192","article-title":"Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells","volume":"67","author":"Makrygiannakis","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102399_bib32","article-title":"Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation","author":"Ytterberg","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.jaut.2019.102399_bib33","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1002\/art.40066","article-title":"Anti-citrullinated protein antibodies are associated with neutrophil extracellular traps in the sputum in relatives of rheumatoid arthritis patients","volume":"69","author":"Demoruelle","year":"2017","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"10","key":"10.1016\/j.jaut.2019.102399_bib34","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/art.38066","article-title":"Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease","volume":"65","author":"Willis","year":"2013","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.jaut.2019.102399_bib35","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.34344","article-title":"Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity?","volume":"64","author":"Demoruelle","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jaut.2019.102399_bib36","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00284-013-0338-1","article-title":"Analysis of fecal Lactobacillus community structure in patients with early rheumatoid arthritis","volume":"67","author":"Liu","year":"2013","journal-title":"Curr. Microbiol."},{"key":"10.1016\/j.jaut.2019.102399_bib37","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.01202","article-title":"Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis","volume":"2","author":"Scher","year":"2013","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.jaut.2019.102399_bib38","first-page":"1500","article-title":"Fecal microbiota in early rheumatoid arthritis","volume":"35","author":"Vaahtovuo","year":"2008","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib39","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/annrheumdis-2018-214514","article-title":"Prevotella copri in individuals at risk for rheumatoid arthritis","volume":"78","author":"Alpizar-Rodriguez","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.jaut.2019.102399_bib40","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1136\/annrheumdis-2012-202127","article-title":"A prediction rule for the development of arthritis in seropositive arthralgia patients","volume":"72","author":"van de Stadt","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.jaut.2019.102399_bib41","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1136\/annrheumdis-2014-205227","article-title":"Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study","volume":"74","author":"Rakieh","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102399_bib42","article-title":"EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis","author":"van Steenbergen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2019.102399_bib43","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/ard.2008.105759","article-title":"Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study","volume":"69","author":"Bos","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2019.102399_bib44","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/art.39297","article-title":"Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease","volume":"67","author":"Ramos-Remus","year":"2015","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"4","key":"10.1016\/j.jaut.2019.102399_bib45","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.semarthrit.2018.04.005","article-title":"Identifying MRI-detected inflammatory features specific for rheumatoid arthritis: two-fold feature reduction maintains predictive accuracy in clinically suspect arthralgia patients","volume":"48","author":"Aizenberg","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jaut.2019.102399_bib46","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1136\/annrheumdis-2015-207991","article-title":"T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals","volume":"75","author":"Hunt","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib47","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/annrheumdis-2012-202753","article-title":"The type I IFN signature as a biomarker of preclinical rheumatoid arthritis","volume":"72","author":"L\u00fcbbers","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102399_bib48","article-title":"How are rheumatologists managing anticyclic citrullinated peptide antibodies-positive patients who do not have arthritis?","author":"Mankia","year":"2019","journal-title":"J. Rheumatol."},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib49","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.22525","article-title":"Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial","volume":"56","author":"van Dongen","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2019.102399_bib50","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","article-title":"Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)","volume":"69","author":"Emery","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib51","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/art.40062","article-title":"Brief report: clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: a trial of methotrexate versus placebo in undifferentiated arthritis as an example","volume":"69","author":"Burgers","year":"2017","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"3","key":"10.1016\/j.jaut.2019.102399_bib52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/ard.2009.119149","article-title":"STIVEA investigators, Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial","volume":"69","author":"Verstappen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2019.102399_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/ard.2009.122473","article-title":"The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis","volume":"69","author":"Machold","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2019.102399_bib54","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/ard.2008.105767","article-title":"Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial","volume":"69","author":"Bos","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102399_bib55","article-title":"Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study","author":"Gerlag","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102399_bib56","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.jaut.2019.102399_bib57","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s11547-019-01002-2","article-title":"Ultrasound imaging in rheumatoid arthritis","volume":"124","author":"Filippucci","year":"2019","journal-title":"Radiol. Med."},{"key":"10.1016\/j.jaut.2019.102399_bib58","article-title":"Imaging in the preclinical phases of rheumatoid arthritis","author":"Zabotti","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9636","key":"10.1016\/j.jaut.2019.102399_bib59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(08)61000-4","article-title":"Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial","volume":"372","author":"Emery","year":"2008","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jaut.2019.102399_bib60","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/ard.2009.117341","article-title":"Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?","volume":"69","author":"Saleem","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.jaut.2019.102399_bib61","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1136\/annrheumdis-2016-209201","article-title":"Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions","volume":"75","author":"Schett","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102399_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key054","article-title":"Secular trends of sustained remission in rheumatoid arthritis, a nationwide study in Sweden","author":"Einarsson","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102399_bib63","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/annrheumdis-2013-204020","article-title":"Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010","volume":"74","author":"Aga","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2019.102399_bib64","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/rheumatology\/key338","article-title":"Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry","volume":"58","author":"Olsen","year":"2019","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.jaut.2019.102399_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1759720X17720366","article-title":"Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations","volume":"9","author":"Ajeganova","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"6","key":"10.1016\/j.jaut.2019.102399_bib66","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/rheumatology\/kem007","article-title":"Assessing remission in clinical practice","volume":"46","author":"Mierau","year":"2007","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.jaut.2019.102399_bib67","doi-asserted-by":"crossref","first-page":"R68","DOI":"10.1186\/ar3785","article-title":"Sustained rheumatoid arthritis remission is uncommon in clinical practice","volume":"14","author":"Prince","year":"2012","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.jaut.2019.102399_bib68","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","article-title":"Defining refractory rheumatoid arthritis","volume":"77","author":"Buch","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib69","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/annrheumdis-2014-207080","article-title":"Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms","volume":"75","author":"Ajeganova","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.jaut.2019.102399_bib70","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/1744666X.2020.1686976","article-title":"Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis","volume":"15","author":"Cavalli","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2019.102399_bib71","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/rheumatology\/key054","article-title":"Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden","volume":"58","author":"Einarsson","year":"2019","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.jaut.2019.102399_bib72","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.20712","volume":"52","author":"Quinn","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.jaut.2019.102399_bib73","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.jaut.2019.102399_bib74","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000445","article-title":"Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone","volume":"3","author":"Keystone","year":"2017","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.jaut.2019.102399_bib75","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1093\/rheumatology\/kez188","article-title":"Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients","volume":"58","author":"Hamann","year":"2019","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.jaut.2019.102399_bib76","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/annrheumdis-2018-214918","article-title":"Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis","volume":"78","author":"Aletaha","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2019.102399_bib77","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-019-0279-6","article-title":"Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets","volume":"15","author":"Aletaha","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib78","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/17512433.2015.1061429","article-title":"Remission in rheumatoid arthritis: is it all the same?","volume":"8","author":"Gul","year":"2015","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.jaut.2019.102399_bib79","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/rheumatology\/kep171","article-title":"Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse","volume":"48","author":"Scir\u00e8","year":"2009","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib80","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/ard.2010.134445","article-title":"Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments","volume":"70","author":"Saleem","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.jaut.2019.102399_bib81","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/rheumatology\/kew037","article-title":"Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy","volume":"55","author":"Horton","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaut.2019.102399_bib82","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.11481","article-title":"Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission","volume":"50","author":"Molenaar","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.102399_bib83","doi-asserted-by":"crossref","DOI":"10.1186\/1478-6354-13-S1-S4","article-title":"Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future","author":"Schett","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.jaut.2019.102399_bib84","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.22190","article-title":"Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression","volume":"54","author":"Brown","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jaut.2019.102399_bib85","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1002\/art.23945","article-title":"An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis","volume":"58","author":"Brown","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.jaut.2019.102399_bib86","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3109\/s10165-012-0690-1","article-title":"Ultrasonography is a potent tool for the prediction of progressive joint destruction during clinical remission of rheumatoid arthritis","volume":"23","author":"Yoshimi","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.jaut.2019.102399_bib87","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez330","article-title":"Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes","author":"Gul","year":"2019","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib88","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jama.2018.21249","article-title":"Achieving clinical remission for patients with rheumatoid arthritis","volume":"321","author":"Aletaha","year":"2019","journal-title":"J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.jaut.2019.102399_bib89","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/annrheumdis-2018-214868","article-title":"Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status","volume":"78","author":"Boeters","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2019.102399_bib90","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000840","article-title":"Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study","volume":"5","author":"Emery","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.jaut.2019.102399_bib91","article-title":"Impact of flare on radiographic progression after etanercept continuation, tapering or withdrawal in patients with rheumatoid arthritis","author":"Smolen","year":"2019","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.jaut.2019.102399_bib92","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2019.102399_bib93","first-page":"1","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2015","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.jaut.2019.102399_bib94","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-019-1937-4","article-title":"The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis","volume":"21","author":"Tanaka","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102399_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/art.40196","article-title":"A phase 3 study evaluating continuation, tapering, and withdrawal of certolizumab pegol after 1 Year of therapy in early rheumatoid arthritis patients","author":"Weinblatt","year":"2017","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.jaut.2019.102399_bib96","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/rheumatology\/keq194","article-title":"Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis","volume":"49","author":"Bejarano","year":"2010","journal-title":"Rheumatology"},{"issue":"10042","key":"10.1016\/j.jaut.2019.102399_bib97","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","article-title":"Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial","volume":"388","author":"Bijlsma","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jaut.2019.102399_bib98","first-page":"1781","article-title":"Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis","volume":"76","author":"Brocq","year":"2009","journal-title":"Jt. Bone Spine"},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib99","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/annrheumdis-2013-204632","article-title":"Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial","volume":"74","author":"Smolen","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102399_bib100","doi-asserted-by":"crossref","first-page":"h1389","DOI":"10.1136\/bmj.h1389","article-title":"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial","volume":"350","author":"van Herwaarden","year":"2015","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.jaut.2019.102399_bib101","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3899\/jrheum.180028","article-title":"Cost-effective tapering algorithm in patients with rheumatoid arthritis: combination of multibiomarker disease activity score and autoantibody status","volume":"46","author":"Hagen","year":"2019","journal-title":"J. Rheumatol."},{"issue":"8","key":"10.1016\/j.jaut.2019.102399_bib102","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/rheumatology\/kev006","article-title":"Predictive value of Doppler ultrasound-detected synovitis in relation to failed tapering of biologic therapy in patients with rheumatoid arthritis","volume":"54","author":"Naredo","year":"2015","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.jaut.2019.102399_bib103","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/annrheumdis-2018-213217","volume":"77","author":"Filippou","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102399_bib104","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-016-0927-z","article-title":"Tapering and discontinuation of TNF-\u03b1 blockers without disease relapse using ultrasonography as a tool to identify patients with rheumatoid arthritis in clinical and histological remission","volume":"18","author":"Alivernini","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.jaut.2019.102399_bib105","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/annrheumdis-2012-201612","article-title":"Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study","volume":"72","author":"Detert","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2019.102399_bib106","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13075-018-1764-z","article-title":"Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study","volume":"20","author":"Inciarte-Mundo","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.102399_bib107","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/ard.2007.073833","article-title":"Abnormal T-cell differentiation persists in rheumatoid arthritis patients in clinical remission and predicts relapse","volume":"67","author":"Burgoyne","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.102399_bib108","article-title":"Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low-disease activity: a systematic literature review","author":"Schlager","year":"2019","journal-title":"Rheumatology"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119308583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119308583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:25:52Z","timestamp":1760257552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841119308583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":108,"alternative-id":["S0896841119308583"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102399","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and cure: The major unmet needs in the management of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2019.102399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102399"}}